8-KLeadership Changes

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Dec 18, 2007)

Filed December 18, 2007For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on December 18, 2007, reporting key executive changes and compensation adjustments. The most significant development is the appointment of Barry E. Greene as President and Chief Operating Officer, a role he assumes in addition to his existing COO responsibilities. This promotion signifies internal growth and increased operational leadership within the company. Concurrently, Dr. John M. Maraganore will continue in his role as CEO, focusing on strategic leadership, while no longer holding the President title. Furthermore, the filing details adjustments to the base salaries and stock option awards for the company's named executive officers for the fiscal year 2008. These changes, approved by the Compensation Committee, reflect an increase in base compensation and the granting of stock options, which aligns executive incentives with shareholder interests through equity participation. The stock options granted have a specific exercise price and vesting schedule, indicating a long-term commitment to performance and retention.

Key Highlights

  • 1Barry E. Greene appointed President and Chief Operating Officer, effective December 12, 2007.
  • 2Dr. John M. Maraganore continues as CEO and principal executive officer, relinquishing the President title.
  • 3Named executive officers received base salary increases for fiscal year 2008.
  • 4Stock options were awarded to named executive officers under the Company’s 2004 Stock Incentive Plan.
  • 5The exercise price for granted stock options is $31.39 per share.
  • 6Stock options have a staggered vesting schedule, with 25% vesting on the first anniversary and incremental vesting thereafter.
  • 7These changes reflect internal leadership development and a focus on executive compensation alignment with company performance.

Frequently Asked Questions

Barry E. Greene's appointment as President and Chief Operating Officer signifies an elevation of his responsibilities within Alnylam. It suggests the company is strengthening its operational leadership and likely preparing for future growth or further development of its product pipeline.

Dr. John M. Maraganore will continue to serve as the Chief Executive Officer, focusing on the company's overall strategy and principal executive duties. By relinquishing the President title, he can dedicate more focus to his CEO responsibilities, while Greene handles operational leadership.

The named executive officers have received increases in their base salaries effective January 1, 2008. Additionally, they were granted stock options with an exercise price of $31.39 per share. These options vest over a four-year period, with initial vesting at one year and subsequent quarterly vesting, aligning executive incentives with long-term company performance.

The stock options were granted with an exercise price of $31.39 per share, which was the closing price on December 12, 2007. The vesting schedule is as follows: 25% of the shares vest on the first anniversary of the grant date, and an additional 6.25% vest at the end of each successive three-month period following the first anniversary, continuing until the fourth anniversary of the grant date.